管理团队

汤楠 博士

创始人、董事长

汤楠博士，普沐生物创始人兼董事长，现任北京生命科学研究所资深研究员。汤楠博士是国际知名的肺纤维化与肺泡再生领域专家，在研究促进肺泡再生的分子和细胞驱动因素方面拥有20余年的经验。她建立了首个可重现人类病理特征的特发性肺纤维化小鼠模型，并系统识别、验证了多个肺部疾病的全新治疗靶点。

汤楠博士于加州大学圣地亚哥分校获得博士学位，在加州大学旧金山分校完成博士后研究。她同时具备执业医师资质，毕业于西安交通大学医学院并获得医学学士学位。

Nan Tang, M.D., Ph.D.

Founder & Chairman
Nan Tang, M.D., Ph.D., is the founder and chairm of pulmongene, and currently the Principal Investigator of NIBS. Dr. Nan is an internationally renowned expert in pulmonary fibrosis and alveolar regeneration and has more than 20 years’ experience in investigating molecular and cellular drivers that promote alveolar regeneration. She established the first authentic IPF mouse model and identified of novel therapeutic targets of lung diseases. Dr. Tang has co-authored 27 publications and holds 5 patents in the areas of lung diseases and alveolar regeneration, the total impact facter exceeds 390. Dr. Nan holds a Ph.D. from the University of California, San Diego, USA and subsequently did her research training in the laboratory of Dr. Gail Martin at the University of California, San Francisco, USA

Rui Zhao, Ph.D.

Vice President, Head of Biology
Dr. Zhaojoined Pulmongene since inception with more than 10 years of experience in lung diseases and novel target discovery. She oversees all early clinical development including target identification & validation, pharmacology, PK/PD, toxicology, biomarker, and clinical pharmacology. Prior to joining Pulmongene, Dr. Zhao served as Principal Investigator III at Genomics Institute of the Novartis Research Foundation (GNF), Novartis, where she lead the respiratory drug portfolio to uncover first-in-class respiratory medicines and oversaw multiple project teams working across different disease areas. Dr. Zhao received her B.S. from China Agricultural University in 2003 and Ph.D. from National Institute of Biological Sciences, Beijing in 2008. She completed herpost-doc training in the laboratory of Dr. Jayaraj Rajagopal at Massachusetts General Hospital (MGH), Harvard Stem Cell Institute.

Samantha Wood

Scientist

Born on March 14, 1879, in the southern German city of Ulm, Albert Einstein grew up in a middle-class Jewish family in Munich. As a child, Einstein became fascinated by music (he played the violin), mathematics and science. He dropped out of school in 1894 and moved to Switzerland, where he resumed his schooling and later gained admission to the Swiss Federal Polytechnic Institute in Zurich. In 1896, he renounced his German citizenship, and remained officially stateless before becoming a Swiss citizen in 1901.

胡稳奇 博士

首席技术官

胡稳奇博士于2023年加入普沐生物，担任首席技术官。他在全球生物制药与生物技术行业拥有20余年丰富的研发与管理经验。

在加入普沐生物之前，胡稳奇博士曾担任北京天广实生物技术股份有限公司董事兼首席科学官。此前，他历任迈博斯生物医药（苏州）有限公司副总裁、中美冠科生物技术有限公司高级总监。在加入中美冠科之前，胡稳奇博士曾在美国默沙东及Verenium 公司（现隶属于巴斯夫）担任多个重要职务，职责不断提升。

胡稳奇博士主导研发了多款治疗性抗体药物，目前均已进入Ⅰ期至Ⅲ期临床试验阶段，并在美国及中国拥有30余项授权专利。

胡稳奇博士于湖南农业大学获得植物生物学博士学位（与密歇根州立大学联合培养项目），并在西安大略大学与圭尔夫大学完成微生物学与免疫学方向的博士后研究。

赵瑞 博士

首席科学官

赵瑞博士于公司创立之初便加入普沐生物，在肺部疾病及新靶点发现领域拥有超过15年的丰富经验。她全面负责公司早期研究与临床开发工作，包括靶点筛选与验证、药理学研究、PK/PD、毒理学、生物标志物以及临床药理学等。

在加入普沐生物之前，赵瑞博士曾任职于诺华制药的诺华研究基金会基因组学研究所（GNF）。在此期间，她负责呼吸系统药物研发管线，致力于开发全球首创（first-in-class）的呼吸系统新药，并领导多个跨疾病领域的项目团队开展研究工作。

赵瑞博士于中国农业大学获得学士学位，于北京生命科学研究所获得博士学位，后在麻省总医院（MGH）及哈佛干细胞研究所完成博士后研究。

滚动至顶部